Unknown

Dataset Information

0

Prescribing Patterns for Treatment of Mycobacterium avium Complex and M. xenopi Pulmonary Disease in Ontario, Canada, 2001-2013.


ABSTRACT: Surveys suggest that clinicians diverge from guidelines when treating Mycobacterium avium complex (MAC) pulmonary disease (PD). To determine prescribing patterns, we conducted a cohort study of adults >66 years of age in Ontario, Canada, with MAC or Mycobacterium xenopi PD during 2001-2013. Using linked laboratory and health administrative databases, we studied the first treatment episode (>60 continuous days of >1 of a macrolide, ethambutol, rifamycin, fluoroquinolone, linezolid, inhaled amikacin, or, for M. xenopi, isoniazid). Treatment was prescribed for 24% MAC and 15% of M. xenopi PD patients. Most commonly prescribed was the recommended combination of macrolide, ethambutol, and rifamycin, for 47% of MAC and 36% of M. xenopi PD patients. Among MAC PD patients, 20% received macrolide monotherapy and 33% received regimens associated with emergent macrolide resistance. Although the most commonly prescribed regimen was guidelines-recommended, many regimens prescribed for MAC PD were associated with emergent macrolide resistance.

SUBMITTER: Brode SK 

PROVIDER: S-EPMC6590764 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5382758 | biostudies-literature
| S-EPMC4766895 | biostudies-literature
| S-EPMC7454113 | biostudies-literature
| S-EPMC4313233 | biostudies-literature
| S-EPMC3986013 | biostudies-literature
| S-EPMC6950658 | biostudies-literature
| S-EPMC5813939 | biostudies-literature
| PRJNA158067 | ENA
| PRJDB9078 | ENA
| S-EPMC7291046 | biostudies-literature